Global Narcolepsy Therapeutics Market to Reach $4,912.3 Million by 2032
Global Narcolepsy Therapeutics Market: Industry Overview
The global narcolepsy therapeutics market is projected to reach $4,912.3 million by 2032 from $915.2 million in 2021 at a CAGR of 15.93% during the forecast period 2022-2032. This The market is driven by certain factors, such as low satisfaction with available therapies, robust pipeline products, rising uptake of narcolepsy awareness programs, and improving diagnosis.
Market Lifecycle Stage
The global narcolepsy therapeutics market is in the rapidly evolving and dynamic stage, which opens ample opportunities for life science companies.Also, companies that are already in the development phase for narcolepsy therapies are trying to bring advanced treatment options to the market to improve the quality of life of people with narcolepsy.
The companies operating in the global narcolepsy therapeutics market are now focusing more on disease-specific and personalized treatment options.Also, major players such as Jazz Pharmaceuticals PLC, Takeda Pharmaceuticals Co.
Ltd, and Bioproject Pharma are investing heavily in research and development for their respective therapeutic products.
Albeit narcolepsy is an orphan disorder with only about 3 million people globally, the existing management of narcolepsy propounds the area as investigational for drug research and development.Currently, all available therapies are symptom-centric and do not cure the condition.
In about 50% of people, disorder onset often occurs prior to age 25 with a delayed diagnosis, especially in adolescents.Insubstantial abilities of existing therapies to cover a complete range of symptoms and insignificant improvement in the quality of life of people with narcolepsy have led to the emergence of several innovative therapies in recent years.
The market witnessed approximately 39 regulatory and legal developments during the time period between January 2019 and May 2022.
In addition, the disorder profoundly increases the psychosocial burden on people with narcolepsy.Associated high treatment costs and dwindled work productivity with reduced income levels are some of the key factors adding to the psychosocial burden for people living with narcolepsy.
Most companies are focusing on expanding their product portfolio with the launch of best-in-class distinctive novel therapeutics and trying to address the limitations and challenges with available therapies in an effort to increase their global footprint alongside.
Segmentation 1: by Indication • Type 1 Narcolepsy • Type 2 Narcolepsy • Secondary Narcolepsy
Due to recent research and development in type 1 narcolepsy, significant therapies with novel mechanisms of action, reduced dosing, and better efficacy are emerging. Therefore, the segment is dominated by type 1 narcolepsy, which held a share of 69.60% in 2021.
Segmentation 2: by Product • Commercialized Products • Pipeline Products
In 2021, the global narcolepsy therapeutics market (by product) is dominated by commercialized products with 100% market share.
Segmentation 3: by Therapeutic Type • Central Nervous System Stimulant • Norepinephrine Reuptake Inhibitor • Histamine-3 (H3) Receptor Antagonist/Inverse Agonist
The global narcolepsy therapeutics market (by therapeutics) is presently dominated by central nervous system stimulant, with a value of $535.3 million, as of 2021.
Segmentation 4: by Country • U.S. • Germany • Italy • France • U.K. • Spain • Japan
In 2021, the U.S. accounted for a share of 93.48% of the global narcolepsy therapeutics market. The segment is expected to reach $4,327.7 million in 2032 from $855.5 million in 2021 at a CAGR of 15.24% during the forecast period 2022-2032.
Recent Developments in the Global Narcolepsy Therapeutics Market
• On March 28, 2022, Jazz Pharmaceuticals PLC divested Sunosi. Axsome Therapeutics, Inc. will expand its presence in neuroscience by acquiring Sunosi (solriamfetol) from Jazz Pharmaceuticals PLC. • On August 31, 2021, Health Canada approved Jazz Pharmaceutical’s Sunosi (solriamfetol) for excessive daytime sleepiness associated with narcolepsy. • On August 10, 2021, Harmony Biosciences LLC’s successful track record of Wakix motivated Blackstone to enter a strategic financing collaboration, where the company agreed to invest up to $330.0 million of financing and growth capital in Harmony Biosciences LLC. • On September 16, 2021, Axsome Therapeutics, Inc. announced the enrolment of the first patient in the new phase 3 clinical trial SYMPHONY (a study evaluating a mechanistic approach to treating narcolepsy) of AXS-12 in narcoleptic patients.
Demand - Drivers and Limitations
Following are the demand drivers for the global narcolepsy therapeutics market: • Large Population of Undiagnosed and Untreated Narcolepsy Population • Increasing Research Funding for Neuroscience • Approval of Advanced Therapies with Novel Mechanism of Action (MoA) • Existing Unmet Needs of Patients and Healthcare Professionals (HCPs)
The market is expected to face some limitations due to the following challenges: • Delayed Diagnosis • Lack of Awareness
How can this report add value to an organization?
Innovation Strategy: The therapeutic segment helps the reader understand the different drug classes being targeted to develop novel and advanced therapies for narcolepsy in the market.
Growth/Marketing Strategy: The global narcolepsy therapeutics market has seen major development by key players operating in the market, such as regulatory and legal developments, clinical developments, synergistic activities, product approvals, product launches and updates, mergers and acquisitions, business expansion and funding, and other developments. The favored strategy for the companies has been regulatory and legal activities along with product approvals to strengthen their position in the market.
Competitive Strategy: Key players in the global narcolepsy therapeutics market have been analyzed and profiled in the study.Moreover, a detailed competitive benchmarking of players operating in the global narcolepsy therapeutics market has been done to help the reader understand how players stack against each other, presenting a clear market landscape.
Additionally, comprehensive competitive strategies such as partnerships, agreements, and collaborations will aid the reader in understanding the untapped revenue pockets in the market.
Key Market Players and Competition Synopsis
The companies that are profiled have been selected based on inputs gathered from primary experts and analyzing company coverage, product portfolio, and market penetration.
Some of the prominent names established in this market are: • Jazz Pharmaceuticals PLC • Harmony Bioscience, LLC • Axsome Therapeutics, Inc. • Avadel Pharmaceuticals PLC • Takeda Pharmaceutical Co Ltd • Sumitomo Pharma Co Ltd • Suven Life Sciences Limited • NLS Pharmaceutics AG • Balance Therapeutics
Countries Covered • U.S. • U.K. • Germany • France • Italy • Spain • Japan
Our reports have been used by over 10K customers, including:
175 pages •
By The Business Research Company
• Sep 2022
Major players in the microbiome therapeutics market are Seres Therapeutics, Enterome Bioscience, Rebiotix, Microbiome Therapeutics, and Ritter Pharmaceuticals. The global microbiome therapeutics market is expected to grow from $0.29 billion in 2021 to $0.39 billion in 2022 at a compound annual growth rate (CAGR) of 34.7%. The microbiome...
Behcet Disease Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update Summary This latest Pharmaceutical and Healthcare disease pipeline guide Behcet Disease - Drugs In Development, 2022, provides an overview of the Behcet Disease (Cardiovascular) pipeline landscape. Behcet...
Histone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC 18.104.22.168) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update Summary According to the recently published report ’Histone Deacetylase 6 - Drugs In Development,...
"Cytokine Release Syndrome (CRS)- Epidemiology Forecast-2032" report delivers an in-depth understanding of the cytokine release syndrome, historical and forecasted epidemiology as well as the cytokine release syndrome trends in the United States, the EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan. Geography...
United Kingdom Monkeypox Therapeutics Market, By Treatment (Smallpox Vaccine, Antivirals, Vaccinia Immune Globulin (VIG)), By End User (Hospitals, Specialty Clinics, Ambulatory Surgical Centers, Others), By Region, Competition Forecast & Opportunities, 2027 The United Kingdom monkeypox therapeutics market is projected...
“Electroencephelographs (EEG)–Pipeline Insight and 2022,” report provides comprehensive insights about 20+ companies and 20+ pipeline devices in Electroencephelographs pipeline landscape. Increased incidence of disorders like Alzheimer’s disease, epilepsy, Dementia, Multiple Sclerosis, Parkinson’s disease, and stroke around the world has been...
Leber Congenital Amaurosis (LCA) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update Summary This latest Pharmaceutical and Healthcare disease pipeline guide Leber Congenital Amaurosis (LCA) – Drugs In Development, 2022, provides an overview of the Leber Congenital...
Resistant Pseudomonas aeruginosa Infections Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update Summary This latest Pharmaceutical and Healthcare disease pipeline guide Resistant Pseudomonas aeruginosa Infections – Drugs In Development, 2022, provides an overview...
242 pages •
By The Business Research Company
• Jun 2022
Coronavirus (COVID-19) Current Therapy Global Market Opportunities And Strategies To 2030: COVID-19 Growth And Change provides the strategists; marketers and senior management with the critical information they need to assess the global coronavirus (COVID-19) current therapy market as it emerges from the COVID 19 shut down. Description: Where...
258 pages •
By Global Industry Analysts
• Oct 2022
Abstract: What’s New for 2022?? Global competitiveness and key competitor percentage market shares Market presence across multiple geographies - Strong/Active/Niche/Trivial Online interactive peer-to-peer collaborative bespoke updates Access to our digital archives and MarketGlass Research...
You can change your Cookie Settings at any time but parts of our site will not function correctly without them.